|Digitineers®: Driven by Science | firstname.lastname@example.org|
The Medical Software Architects
Digitineers® is the home of experts for medical domains, medical data domains and medical software achitecture. At Digitineers we work with data domains experts, and partnered software and AI engineers at the cutting edge of DTx. Whilst we contribute to a major digitization shift that's already underway it is our philosophy to design products that preserve humanity.
Digitineers® team members´ background is Excellence in Science. Coming from medicine and neuroscience the development experience of team members goes back to the successful codevelopment of electronic neuroimplants up to CE certification. Today Digitineers is breaking new ground upstream to hybrid AI. Digitineers combines product architecture and design with user knowledge and experience in the context of digital knowledge and thinking. And: we have built networks for a valuable transfer of knowledge. The result: an eco-system with digital thought leaders and partners with diverse inspirations for everyone involved.
Digitineers® can be disruptive. More than 70 patents of team members speak for this.
Digitineers emerged from graduates and scientists of the University of Munich (LMU) and the University of Tuebingen, both in Germany. Our international education and professional experience covers both the EU and the US.
Our DTx Products
Vertidisan® is a DTx for the treatment of vestibulopathies. It is a CE marked medical device. Since the year 2021 it is available to private patients. Free sale for German GKV patients is planned from 2023. For product details see here. Vertidisan is powered by NEGDISAN, our Next-Generation Medical DTx Architecture and Development platform.
NEGDISAN is our Next-Generation Medical Software Architecture and Development tool. NEGDISAN is a development and production platform for developing, manufacturing and scaling AI-driven (AI DTx, Artificial Intelligence Digital Therapeutics) and non-AI-driven digital therapeutics. The platform is used to produce DTx for patients as well as DTx for use in space. NEGDISAN contributes to a major health care digitization shift that's already underway.
Our DTx Pipeline
Space Research: DTx Development for Prevention and Treatment of Inflight and Postflight Space Motion Sickness (SMS)
Problem. Space motion sickness (SMS) is observed in approximately 70% of astronauts in space and in addition post flight. Even more are expected in future space tourists. Drugs are available but may produce severe adverse events. Furthermore, during longer space missions drugs may lose their efficacy.
Solution. A DTx (digital therapeutics) possessing the USP to reduce or remove SMS in a higher percentage than drugs or physiotherapy, which is available anytime and anywhere both on earth for preflight prevention and for post flight treatment and in space. In contrast to drugs it does not loose efficacy and does not produce significant adverse events and which in addition covers stress and coping inability. Verti-Disan® will be developed as a digital therapeutics (DTx) to provide a standalone preventive and therapeutic solution.
The device is thought to
--Control a sensory-conflict rearrangement of the terrestrial gravity-related relationship between different inputs that are provided by the eyes, skin, joints, muscles, and especially vestibular receptors in the inner ear.
--Stabilize sensory-motor disturbances.
--Stop illusion of self-motion associated with spatial disorientation.
--Induce head movements in the pitch and roll planes. They result in stabilizing cues being transmitted to the central nervous system regions responsible for central integration of the semi-circular canals (angular acceleration) and the otolith organs (linear acceleration).
--Provide Coriolis cross-coupling stabilization to be achieved by means of sudden ac- and decelerations from constant velocity rotation which are elicited by angular and linear movements, oculomotor and posture responses to optokinetic stimulations, and responses to caloric stimulation.
Space Related Efficacy and Safety. After approval by the relevant State approved Ethics Committee prospective controlled clinical studies are legally and ethically possible investigating feasibility, efficacy and safety of the DTx for prevention and treatment of inflight and postflight vestibular disorders. Studies may start 2023 and may include parabolic flights and space flights. As result the DTx could be a standalone preventive and therapeutic solution for astronauts and space tourists to prevent from and to treat inflight and postflight SMS.
D-72072 Tübingen, Germany
Digitineers is a Registrated Medical Device Manufacturer and has established a Quality Management System according to ISO 13485.